The safety and efficacy of nephron sparing surgery in T1N0M0 renal cell carcinoma

Athar R. Asimi; Mohammad S. Wani; Mohammad I. Lone

doi:10.18203/2349-2902.isj20180011

Authors

Athar R. Asimi Department of Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
Mohammad S. Wani Department of Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India
Mohammad I. Lone Department of Pathology, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2349-2902.isj20180011

Keywords:

Cell carcinoma, Nephron, Nephron sparing surgery, Radical nephrectomy

Abstract

Background: Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasm arising from the kidney. Objective was to explore the safety and efficacy of nephron sparing surgery (NSS) for T1N0M0 renal cell carcinomas (RCC) and to assess the oncological outcome of NSS in T1N0M0 RCC.

Methods: A total of 31 cases were enrolled for the study of which 11 (35.5%) underwent NSS and 20 (64.5%) underwent radical nephrectomy (RN). The clinical results were followed up and comparatively analyzed.

Results: NSS was performed using a margin of 1cm, no positive surgical margin was detected. The mean blood loss and mean duration of surgery in NSS and RN was comparable. Among all one patient from NSS group experienced urinary leak which was managed by placement of DJ stent. The overall complication rate was 9.1% in NSS. Lab. tests before surgery and after surgery at 6month was done in the both groups and results obtained was within normal limits. Only one patient developed metastasis from NSS group and died at 14th month of fallow-up, whereas neither metastasis nor mortality were recorded in RN group.

Conclusions: Nephron sparing SURGERY has proven to be a safe and effective approach for Renal cell carcinoma with comparable clinical results to radical nephrectomy especially in tumour ≤4cm.

Metrics

Metrics Loading ...

References

Jonasch. In: Kantarjian HM, Wolff RA, Koller CA, eds. Renal cell carcinoma. MD Anderson Manual of Medical Oncology. New York, NY: McGraw-Hill; 2006.

Linehan MW, Berton Z, Bates S. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer of kidney and ureter. Principles and Practice of Oncology. 6th Ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1362-1396.

Simon JW, Marshall FF. In: Abeloff MD, Armitage J, Niederhuber J, Kastan M, McKenna W, eds. Kidney and ureter. Clinical Oncology. 2nd Ed. New York, NY: Churchill Livingstone; 2000:1784-1799.

Chow WH, Devesa SS, Warren JL. Rising incidence of renal cell cancer in the United State. JAMA 1999;281:1628.

Chow WH, Devesa SS. contemporary epidemiology of renal cell. Cancer. 2008;14:288.

Jemal A, siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71.

Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, et al. Active treatment of localized renal tumors may not impact overall survival in patient 75 years of age or older. Cancer. 2010 Jul 1;116(13):3119-26.

Hollingswoth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: aneed to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331.

Herr HW, Lee CT, Sharma S, Hilton S.Radiographic versus pathologic size of renal tumors: implications for partial nephrectomy. Urology. 2001;58:157.

Choyke PL. Radiologic imaging of renal cell carcinoma: its role in diagnosis. In:Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006:709-723.

American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th Ed. New York. Springer; 2010:479-486.

Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):801-7.

Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, based on November 2011 SEER data submission. April 2012.

Novick AC. The role of nephron-sparing surgery for renal cell carcinoma. Eur Urol. 1990;18(2):24-5.

Novick AC. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med. 2002;53:393-407.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004;351(13):1296-305.

Novick AC. Nephron-sparing surgery for renal cell carcinoma. Br J Urol. 1998;82(3):321-4.

Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW, Thuroff JW. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. J Urol. 2006;175(6):2027-31.

Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171(6 Pt 1):2181-5.

Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urol. 2011 Apr 30;59(4):543-52.

Roos FC. Department of Urology, Medical Center, Johannes Gutenberg University, Mainz, Germany Received 16 August 2011; Accepted 8 October 2011. Urology. 2012;79(3):607-614.

Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill IS et al. Factors predicting renal functional outcome after partial nephrectomy. J Urol. 2008 Dec 31;180(6):2363-9.

Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, et al. Morbidity and clinical outcome of Nephron-Sparing Surgery in relation to tumour size and indication. European Urol. 2007;52(1):148-54.

Becker F, Siemer S, Hack M, Humke U, Ziegler M, Stöckle M. Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4cm. European urology. 2006 Jun 30;49(6):1058-64.

Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol. 2001 Jul 31;166(1):6-18.

Becker F, Siemer S, Humke U, Hack M, Ziegler M, Stöckle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: long-term survival data of 216 patients. European Urol. 2006 Feb 28;49(2):308-13.

Pahernik S, Roos F, Hampel C, Gillitzer R, Melchior SW, Thüroff JW. Nephron sparing surgery for renal cell carcinoma with normal contralateral kidney: 25 years of experience. J Urol. 2006 Jun 30;175(6):2027-31.

Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. InMayo Clinic Proceedings. 2000;75(12):1236-42.

Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000 Mar 31;163(3):730-6.

Corman JM, Penson DF, Hur K, Khuri SF, Daley J, Henderson W, et al. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU International. 2000 Nov 1;86(7):782-9.

Shekarriz B, Upadhyay J, Shekarriz H, Goes A, Bianco FJ, Tiguert R, Gheiler E, Wood DP. Comparison of costs and complications of radical and partial nephrectomy for treatment of localized renal cell carcinoma. Urology. 2002 Feb 28;59(2):211-5.

Novick AC, Streem SB. Surgery of the kidney, in Campbell’s Urology, Walsh PC, Retik AB, Vaughan ED, Wein AJ Eds. 7th ed. WB Saunders, Philadelphia, Pa, USA;1998:2973-3061.

Zucchi A, Mearini L, Mearini E, Costantini E, Vivacqua C, Porena M. Renal cell carcinoma: histological findings on surgical margins after nephron sparing surgery. J Urol. 2003 Mar 31;169(3):905-8.